Modified growth-hormone fragment · Fact sheet
AOD-9604
Also known as AOD9604 · Tyr-hGH 177–191
AOD-9604 is a modified fragment of human growth hormone investigated for fat metabolism. Human safety studies do not establish the fat-loss and joint-repair benefits often associated with it, and it is not FDA approved.
What is AOD-9604?
AOD-9604 is a short synthetic fragment, not full-length human growth hormone. Its development aimed to separate effects on fat metabolism from other growth-hormone effects.
Benefits & claims
Interest centers on fat loss without the broader effects of growth hormone, and on claims about cartilage or injury recovery. These are separate claims and need separate human outcome evidence.
What the evidence supports
- Controlled human exposure has been studied; the cited safety analysis reported generally similar tolerability to placebo under study conditions.
- That finding cannot establish clinical benefit or the safety of different products and routes.
Research areas
- Obesity
- Fat metabolism
- Short-term tolerability
Dosage & frequency
No established human regimenAOD-9604 is a growth-hormone fragment studied for obesity. Human research has not established an effective approved weight-loss regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- AOD-9604 is not full-length growth hormone and is not the same molecule as every product described as HGH fragment.
Interactions & precautions
- Human interaction data do not establish compatibility with other hormone or weight-management treatments.
What is still unresolved
- A reliably effective amount, frequency, route, and long-term safety profile remain unresolved.
Side effects & risks
- FDA identifies immune-response and impurity concerns and insufficient safety information.
- The available studies cannot reliably exclude uncommon or long-term harms.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceA published analysis pools six controlled human studies to discuss tolerability. It is not proof of effective weight reduction or joint repair, and the authors had development-company affiliations.
Studies
Pooled safety analysis of six controlled trials; development-company conflicts and route limits matter.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Less hunger alongside tirzepatide
A commenter reported more sustained appetite suppression after adding a product labeled AOD-9604 while already using tirzepatide.
Reported use in this account
- Product
- Product described as AOD-9604
- Amount
- 250 mcg
- Frequency
- Every weekday morning
- Route
- Not specified clearly
- Duration
- Four weeks
Other exposures described: Tirzepatide, reported at 5 mg weekly
Concurrent tirzepatide prevents attribution to AOD-9604. The account does not verify product identity or establish an independent weight-loss effect.
Read the appetite accountWeight: reported experiences
Weight loss during several simultaneous changes
A person reported faster weight loss while using AOD-9604 and semaglutide, exercising, watching food intake and paying attention to sleep.
Reported use in this account
- Product
- Product described as AOD-9604
- Amount
- Not specified clearly
- Frequency
- Five days a week
- Route
- Injection; type not stated
- Duration
- An initial three-week exposure
Other exposures described: Semaglutide, described as weekly
Several changes occurred together. The account cannot separate AOD-9604 from semaglutide, diet, activity or ordinary weight fluctuations.
Read the weight-loss accountNo added change after seven weeks
The original poster in that discussion described seven weeks of AOD-9604 alongside Ozempic without noticing a difference in a weight-loss plateau.
Reported use in this account
- Product
- Product described as AOD-9604
- Amount
- Not specified clearly
- Frequency
- Daily in the morning
- Route
- Injection; type not stated
- Duration
- Seven weeks
Other exposures described: A weekly product called 'OZ' by the author
This is an uncontrolled combination experience. It does not establish ineffectiveness or predict another person's result.
Read the contrasting plateau accountNo clear change: reported experiences
No added change after seven weeks
The original poster in that discussion described seven weeks of AOD-9604 alongside Ozempic without noticing a difference in a weight-loss plateau.
Reported use in this account
- Product
- Product described as AOD-9604
- Amount
- Not specified clearly
- Frequency
- Daily in the morning
- Route
- Injection; type not stated
- Duration
- Seven weeks
Other exposures described: A weekly product called 'OZ' by the author
This is an uncontrolled combination experience. It does not establish ineffectiveness or predict another person's result.
Read the contrasting plateau accountApproval status
AOD-9604 has no FDA-approved therapeutic product. FDA compounding committee consideration is a separate process and does not authorize weight-loss or recovery claims.
No FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Durable, meaningful weight-loss benefit
- Human joint-repair outcomes
- Safety across formulations and routes
Summary
AOD-9604 has human research history, but the evidence reviewed here does not establish it as a weight-loss or recovery treatment.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- journalAOD-9604 human safety and tolerability analysis
Pooled safety analysis of six controlled trials; development-company conflicts and route limits matter.
- fdaFDA advisory committee: AOD-9604 review
December 2024 meeting summary documenting consideration of AOD-9604 for the compounding bulks list.